• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: Where Do You Stand on Product Exclusivity Protections?


When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.

What best describes your opinion about the US patent system as it relates to biologics medicine?

It ensures that innovator companies are rewarded fairly and incentivized to develop new medicines.
Patents issued after a product receives FDA approval should be limited.
Concerns about patents preventing biosimilar competition are exaggerated.
Patents have burdened the health care system with high costs and lack of competition.
Related Videos
Ha Kung Wong, JD
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Related Content
© 2024 MJH Life Sciences

All rights reserved.